Tuesday
SESSION 17: NATURAL HISTORY, BEST MEDICAL TREATMENT, PREVENTION OF ARTERIOSCLEROSIS AND ITS COMPLICATIONS
SESSION 17 SCHEDULE
6:43 AM - 6:48 AM Can Medical Treatment Slow The Growth Of Small AAAs
  Presenter(s):Frank A. Lederle, MD  
  View Abstract      
6:49 AM - 6:54 AM Are There New Medical Techniques For Limiting AAA Growth With Drugs (Telmisartan) And Cell Therapy: How Can They Work
  Presenter(s):Ronald L. Dalman, MD  
  View Abstract      
6:55 AM - 7:00 AM Are Statins Decreasing The AAA Rupture Rate: Results From A Danish Nationwide Population-Based Study
  Presenter(s):Jes S. Lindholt, MD  
  View Abstract      
7:01 AM - 7:06 AM A New Agent PCSK9 To Lower LDL: How Low Can LDL Go And Is It Safe
  Presenter(s):Ron Waksman, MD  
  View Abstract      
7:07 AM - 7:12 AM What Is The Association Between The A/B Index And MI And Stroke Risk: Can It Be Altered; What Is The Association Between Obesity And Vascular Disease In Various Vascular Beds: When Is Being Fat Good
  Presenter(s):Caron B. Rockman, MD  
  View Abstract      
7:13 AM - 7:18 AM DEBATE: Statins Have No Role To Play In Primary Prevention And Should Be Avoided In Most Patients
  Presenter(s):Sherif Sultan, MD, FRCS, EBQS-VASC  
  View Abstract      
7:19 AM - 7:24 AM DEBATE: Nonsense: Statins Are A Game Changer, A Miracle Drug: They Should Be Used More Widely In Primary Prevention: Optimal Dosage Of Which Drug
  Presenter(s):Bruce A. Perler, MD, MBA  
  View Abstract      
7:25 AM - 7:30 AM Statins In Vascular Patients: Are There Non-Responders And Responders – How To Tell And What To Do With Non-Responders: What To Do When Patients Have “Apparent Toxicity”: How To Load Preop And Preprocedurally
  Presenter(s):Don Poldermans, MD  
  View Abstract      
7:31 AM - 7:36 AM Optimal Beta Blocker Management In Patients Requiring Vascular Surgery Or Intervention: Current Facts And Optimal Dosing And Drug
  Presenter(s):Jan M.M. Heyligers, MD, PhD, FEBVS  
  View Abstract      
7:35 AM - 7:45 AM Panel Discussion
END OF SESSION 17
previous next